GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WGSWW 09.27.2024

Full Press ReleaseSEC FilingsOur WGSWW Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - GeneDx Announces Preliminary 2024 Financial Results

Recent Filings

  • 01.16.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - 3 Initial statement of beneficial ownership of securities
  • 01.13.2025 - EX-99.1 EX-99.1
PDF Version

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

STAMFORD, Conn.--(BUSINESS WIRE)--Sep. 27, 2024--GeneDx(Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as ofSeptember 23, 2024, the compensation committee of GeneDx’s board of directors granted a total of 7,700 restricted stock units (“RSUs”) to two newly hired employees as inducements material to each employee entering into employment withGeneDx. The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement RSUs will vest in equal annual installments over the four-year period following the grant date, subject to the employee’s continued service with the Company on each applicable vesting date. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.

AboutGeneDx

AtGeneDx(Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visitgenedx.comand connect with us onLinkedIn,X,Facebook, andInstagram.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20240926347394/en/

Investor Relations:investors@GeneDx.com

Media:press@GeneDx.com

Source:GeneDx

PDF Version
Subscribe to Alerts
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com